<![CDATA[Tuberculosis is an infectious disease due to Mycobacterium tuberculosis germ that can infect several organs, including the lungs, kidneys, and bones. The goal of treatment of tuberculosis is tuberculosis bacilli destroy quickly and prevent recurrence. First category treatment of tuberculosis is isoniazid, rifampin, streptomycin, ethambutol, and pyrazinamide. Although the most anti-tuberculosis drug is acceptable in therapy, but have potentially toxic effects hematologic reactions such as agranulocytosis, eosinophilia, thrombocytopenia, and anemia. This research aims to know the correlation between anti-tuberculosis drug consumption in pulmonary TB patients against anemia. Method of this research was Analytical Survey with a Cross-Sectional design. The average results of red blood cell count for 0 months 5,16 106/uL, 2 months 4,39 106/uL and 6 months 4,61 106/uL, haemoglobin levels for 0 month 15,17 g/dL, 2 months 12,73 g/dL and 6 months 13,28 g/dL as well as hematocrit value for 0 month 44,26 %, 2 months 38,24 % and 6 months 39,04 %. From Spearman statistics analytical was obtained significant of red blood cell count 0.004 < α (0.05), levels of hemoglobin 0.007 < α (0.05) and the value of hematocrit 0.015 < α (0.05), it was concluded there was correlation between long consumption of anti-tuberculosis drug with anemia and the value of the correlation coefficient count of red blood cells -0.531, levels of hemoglobin-0.479 as well as the value of hematocrit -0.440 means has the power correlations are medium. Further research is recommended to use different parameters such as the number of platelets, AST/ALT levels and should use the same patient sample or from 0 months up to 6 months]]>
